These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30910600)

  • 1. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
    Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
    Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
    Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
    Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.
    Makras P; Yavropoulou MP; Polyzos SA; Papapoulos SE; Georgakopoulou D; Papatheodorou A; Anastasilakis AD
    Osteoporos Int; 2024 Feb; 35(2):365-370. PubMed ID: 37783758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.
    Tsourdi E; Makras P; Rachner TD; Polyzos S; Rauner M; Mandanas S; Hofbauer LC; Anastasilakis AD
    Bone; 2019 Mar; 120():44-49. PubMed ID: 30292818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease.
    Furman K; Gut P; Sowińska A; Ruchała M; Fichna M
    Endocrine; 2024 May; 84(2):711-719. PubMed ID: 38334892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
    Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
    Hong N; Shin S; Lee S; Kim KJ; Rhee Y
    Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
    Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
    BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
    Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
    J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?
    Grassi G; Ghielmetti A; Zampogna M; Chiodini I; Arosio M; Mantovani G; Eller-Vainicher C
    J Clin Endocrinol Metab; 2024 Sep; 109(10):e1817-e1826. PubMed ID: 38609157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.